The M 4 receptor is a compelling therapeutic target, as this receptor modulates neural circuits dysregulated in schizophrenia, and there is clinical evidence that muscarinic agonists possess both antipsychotic and procognitive efficacy. Recent efforts have shifted toward allosteric ligands to maximize receptor selectivity and manipulate endogenous cholinergic and dopaminergic signaling. In this study, we present the pharmacological characterization of LY2119620
Introduction
Muscarinic acetylcholine (ACh) receptors (M 1 -M 5 ) regulate the action of the neurotransmitter ACh, whose signaling roles in the central nervous system include modulation of processes of mood, cognition, exocrine gland function, and smooth muscle control (Wess et al., 2007; Young et al., 2010; Wess, 2012) . The demonstrated antipsychotic efficacy of muscarinic receptor agonists in both preclinical and clinical studies makes this G protein-coupled receptor (GPCR) subfamily attractive targets for the treatment of Alzheimer's disease and schizophrenia (Bodick et al., 1997; Bymaster et al., 2002; Shekhar et al., 2008; reviewed in Felder et al., 2012; Jones et al., 2012; McKinzie and Bymaster, 2012) . A key bottleneck to research and therapeutic development efforts for the muscarinic ACh receptor family has been the lack of receptor subtype-selective pharmacological tools to help determine the physiologic relevant family member(s) to target for various indications. However, over the past decade, several muscarinic subtype-selective small molecule ligands have emerged through the successful targeting of unique allosteric binding sites generally located on the exterior surface loops of the receptors [e.g., M 1 (Daval et al., 2013) , M 2 (Huang et al., 2005) , M 4 (Nawaratne et al., 2010) , M 5 (Bridges et al., 2009)] . Within this work, we characterize the allosteric-site ligand LY2119620 (3-amino-5-chloro-N-cyclopropyl-4-methyl-6 -[2-(4-methylpiperazin-1-yl)-2-oxoethoxy] thieno[2, 3-b] pyridine-2-carboxamide) and demonstrate that it is a high-affinity M 2 /M 4 receptor-selective positive allosteric modulator (PAM).
LY2119620 was originally synthesized following hit expansion from a small-molecule screening effort for M 4 receptorselective allosteric ligands beginning in 1998, a synthetic campaign that also resulted in LY2033298 (3-amino-5-chloro-N-cyclopropyl-6-methoxy-4-methyl-thieno[2,3-b] pyridine-2-carboxamide) built from the same thieno[2, 3-b] ABBREVIATIONS: ACh, acetylcholine; CHO, Chinese hamster ovary; GPCR, G protein-coupled receptor; GppNHp, g) 3-amino-5-chloro-N-cyclopropyl-6-methoxy-4-methyl-thieno[2,3-b] pyridine-2-carboxamide; LY2119620, 3-amino-5-chloro-N-cyclopropyl-4-methyl-6-[2-(4-methylpiperazin-1-yl)-2-oxoethoxy] thieno[2, 3-b] pyridine-2-carboxamide; scaffold (Chan et al., 2004) . After the 2004 patent filing by Eli Lilly (Rubio and Hillard, 2006) , studies on molecules such as LY2033298 (Chan et al., 2008; Nawaratne et al., 2008 Nawaratne et al., , 2010 Leach et al., 2010 Leach et al., , 2011 Suratman et al., 2011; Gannon and Millan, 2012; Valant et al., 2012) and others, e.g., VU10010 Shirey et al., 2008; Bridges et al., 2010 [http://www.ncbi.nlm.nih.gov/books/NBK143196/]; Lewis et al., 2010; Dencker et al., 2012; Salovich et al., 2012; Huynh et al., 2013; Le et al., 2013) , explored the structureactivity relationship around this scaffold and the in vivo efficacy of such molecules in animal models. Concomitant structure-function work using methods such as site-directed mutagenesis have allowed the mapping of the various ligand binding sites to the M 4 receptor and, in one instance, the M 2 receptor, and revealed critical regions involved in the receptor activation mechanism (Nawaratne et al., 2008 (Nawaratne et al., , 2010 Leach et al., 2011; Suratman et al., 2011; Valant et al., 2012) . The resultant body of knowledge collected on this M 4 receptor-PAM scaffold over the past 15 years allowed us to successfully support the recent breakthrough crystallization efforts of M 2 receptor active-state structure (Kruse et al., 2013) . Working from the necessity of finding a M 2 receptor-selective allosteric binder that could potentiate the already potent agonist, iperoxo, we undertook the characterization of the LY2119620 ligand. The advantage of this ligand over molecules such as LY2033298 was that it had greater M 2 receptor PAM activity when paired with ligands like oxotremorine M (Oxo-M). In the present work, we extend the preliminary pharmacological characterization of LY2119620 presented in the structural study (Kruse et al., 2013) to the study of all five muscarinic receptor subtypes, in both in vitro binding and G protein functional assays, to rigorously evaluate the pharmacology of LY2119620. These studies reveal LY2119620 to be a M 2 /M 4 receptor-selective PAM of both orthosteric ligand binding and receptor G protein signaling; to display evidence of probe dependence (differences in cooperativity observed with different orthosteric-allosteric pairings); and to positively modulate the potent muscarinic-agonist iperoxo at both the M 2 and M 4 receptor subtypes.
Materials and Methods
Chinese hamster ovary (CHO) cell lines stably expressing human M 1 receptor [B max N-methylscopolamine (NMS) 5 4.4 pmol/mg membrane; 
GTPgS-Binding Assays
The level of G protein activation was measured by the amount of nonhydrolyzable GTPgS bound to G ai subunit. The GTPgS-binding was determined using a scintillation proximity assay-bead antibody capture technique (DeLapp et al., 1999) . Note for the studies with iperoxo and the M 2 receptor that a noncommercial membrane source was used, specifically 25 mg M 2 receptor P1 membrane preparations of a CHO cell line stably expressing human M 2 muscarinic receptor (B max 5 0.25 6 0.007 pmol/mg membrane) were used. Otherwise, 20 mg commercial M 1 -M 5 receptor-expressing membranes were used (PerkinElmer). An EC 50 value for each response curve was determined by fitting the agonist response data to a three-or four-parameter fit model (GraphPad Prism; GraphPad Software, San Diego, CA).
Agonist-Binding Experiments. For the agonist GTPgS-binding curves, 20 mg membranes were incubated in assay buffer (20 mM HEPES, 100 mM NaCl, 0.2 mM EDTA, 1 mM GDP, and 10 mM MgCl 2 , pH 7.4), 500 pM GTPgS, and varying concentrations of the orthosteric ligands [ACh, iperoxo, amino]carbonyl]oxy]-N,N,N-trimethyl-2-butyn-1-aminium chloride), and pilocarpine, or LY2119620] for 40 minutes at room temperature with mixing. The Ga subunits were then captured using anti-rabbitconjugated scintillation proximity assay beads (PerkinElmer; 1.25 mg/reaction), Gai antibody (Santa Cruz Biotechnologies, Santa Cruz, CA; 1.3 mg/reaction), and Nonoidet P40 (Roche, 0.1% final concentration) during a 3-hour room temperature incubation. The radioactivity counts of the bound GTPgS were determined by scintillation spectrophotometry (Wallac Trilux; PerkinElmer). An EC 50 value was determined by fitting the agonist response data using a three-parameter fit model (GraphPad Prism).
Interaction Experiments. The GTPgS-binding experiment was run as above, except the orthosteric agonist concentration-response curve was measured in the presence of varying concentrations of allosteric ligand LY2119620 (0-10 mM). EC 50 values at each concentration of LY2119620 were determined.
Allosteric EC 50 Modulation Analysis. The ability of LY2119620 to act as an allosteric modulator was quantified by determining the following: 1) the affinity of LY2119620 for the free receptor (K B ), and 2) the magnitude and direction of the LY2119620 effect on a given orthosteric ligand's affinity by the cooperativity factor a (described in Christopoulos and Kenakin, 2002) . The K B and a values were determined by fitting the eight dose-response curves (acquired in the presence of varying LY2119620 concentration) shown in each panel of Fig. 3 to the allosteric EC 50 shift equation in GraphPad v6.7.
Radioligand-Binding Assays
Binding assays were performed in 20 mM HEPES, 100 mM NaCl, and 10 mM MgCl 2 , pH 7.4 (binding buffer), unless noted. Studies were carried out using commercially prepared CHO membranes expressing the various muscarinic receptor subtypes (PerkinElmer). Reactions were stopped by rapid filtration on a TOMTEC 96-well cell harvester (Tomtec, Hamden, CT). Nonspecific binding was determined using 10 mM atropine. Radioactivity retained on the filter mat was counted on a scintillation spectrophotometry (Wallac 1205 Beta-plate; PerkinElmer). Data were fit to appropriate models using GraphPad Prism 6.7 software (GraphPad Software).
[ [ for an additional 30 minutes. The specific binding versus time data were fit to a one-site specific binding model. Fig. 2 ). The ChengPrusoff model was used to fit the K i of iperoxo in the absence and presence of LY2119620 (Cheng and Prusoff, 1973) .
Results

Modulation of Receptor G Protein-Coupled Signaling by Allosteric Ligand, LY2119620
To investigate the selective allosteric modulation of the M 2 and M 4 receptors, we initially used receptor G protein-coupled signaling at all muscarinic subtypes (M 1 -M 5 ). As allosteric ligands such as LY2119620 ( Fig. 1 ) can demonstrate orthosteric probe-dependent binding (Kenakin, 2007; Leach et al., 2010; Valant et al., 2012) , studies were carried out in the presence of three orthosteric agonists, iperoxo, Oxo-M, or ACh.
Characterization of High-Efficacy Agonist, Iperoxo, at the M 4 Receptor
The agonist, iperoxo, has been reported to have both enhanced affinity and higher efficacy at the M 2 receptor compared with ACh (Langmead and Christopoulos, 2013; Schrage et al., 2013) . As this superagonism had not been extensively explored at the M 4 receptor, concentration-response curves for the full agonists ACh, Oxo-M, and iperoxo, and partial-agonist McN-A-343 were carried out using [ 35 S]GTPgS-binding experiments. This assay format was used as it directly measures G protein activation, the first step in GPCR signal transduction. Oxo-M, ACh, and McN-A-343 were selected to calibrate the assay for exploration of the allosteric compound, LY2119620. The potencies of iperoxo at the M 2 receptor (2.12 6 0.0953 nM) and at the M 4 receptor (8.47 6 3.00 nM) are much greater than the respective EC 50 values of 118 6 31.7 nM and 514 6 22.0 nM observed for ACh. Under the conditions tested, no differences in the maximal response elicited by iperoxo, Ach, or Oxo-M were observed (Fig. 2) . GTPgS-binding assays were used to measure whether LY2119620 showed allosteric agonism (activity in the absence of orthosteric ligand). An agonist response curve for LY2119620 in the absence of nonendogenous orthosteric compound was measured at the M 2 (s) and M 4 receptor (u); these data were normalized to the maximal ACh response at these receptors, M 2 (d) and M 4 (gray square). Data curves presented are the means 6 S.E.M. of three independent experiments conducted in duplicate.
Characterization of Allosteric Agonism of LY2119620 Alone
Binding studies with a radiolabeled form of LY2119620, [ 3 H]LY2119620, showed no detectable binding of the molecule in the absence of orthosteric ligand at the M 1 -M 5 receptor subtypes (Schober et al., 2014) . The intrinsic agonist activity of LY2119620 was also assessed by running G protein activity assays. For these GTPgS experiments, membranes were incubated with LY2119620 in the absence of exogenous agonist, and the resultant concentration-response curves were normalized as a percentage of the maximal ACh response. As shown in Fig.  2C , LY2119620 showed a modest allosteric agonism of 23.2 6 2.18% and 16.8 6 5.01% at the M 2 and M 4 receptors, respectively. This agonism was less than that observed for the partial agonist control compound McN-A-343 shown in Fig. 2A . Minimal allosteric agonism (,20%) was observed for LY2119620 at the M 1 , M 3 , and M 5 receptors (Supplemental Fig. 1 ).
Characterization of Allosteric
35 S]GTPgS-binding experiments were run to verify that LY2119620 potentiates the activity of an orthosteric agonist ligand, and to determine the degree of cooperativity between the orthosteric-allosteric sites. These experiments paired LY2119620 with agonists, ACh, Oxo-M, or iperoxo, and were run at all muscarinic receptor subtypes (M 1 -M 5 ). The M 1 /M 3 /M 5 receptor subtypes showed minimal differences in EC 50 values for all agonists tested (data for iperoxo and Oxo-M not shown; data for ACh shown in Supplemental Fig. 1) . Figure 3 shows positive cooperativity between LY2119620 and all agonists, with larger potentiation generally noted at M 4 than M 2 . These changes were quantified using the allosteric ternary complex model (Christopoulos and Kenakin, 2002) . The variable K B estimates the affinity of LY2119620 for the allosteric binding site on the unoccupied receptor and was found to be consistently about 1.9-3.4 mM (Fig. 3, insets) . The cooperativity factor a, which quantifies the affinity change of one ligand by the other ligand when both are bound to the receptor simultaneously, varied widely depending on the agonist-LY2119620 pairing. LY2119620 and ACh binding led cooperativity factors of 19.5 and 79.4 for the M 2 receptor and the M 4 receptor, respectively (Fig. 3, A and B) . The cooperativity factor of 79.4 at the M 4 receptor suggests that a higher degree of positive cooperativity exists between LY2119620 and ACh than the previously described allosteric M 4 . M 2 receptor modulator, LY2033298 (Chan et al., 2008; Nawaratne et al., 2010) . The Oxo-M and LY2119620 pairing showed the highest degree of cooperativity with an a factor of 50.1 and 282 for the M 2 receptor and M 4 receptor, respectively (Fig. 3, C and D) . The iperoxo and LY2119620 pairing showed the most modest cooperativity with an a factor of 14.5 at the M 2 receptor and 3.9 at the M 4 receptor (Fig. 3, E and F) . Additionally, unlike the other allosteric-orthosteric pairings (ACh and Oxo-M), LY2119620 showed a higher degree of cooperativity with iperoxo at the M 2 receptor rather than the M 4 receptor. Table 1 summarizes the agonist EC 50 values for each concentration of LY2119620 tested.
Ligand-Binding Studies of LY2119620 to the M 2 and M 4 Receptors
Saturation-Binding Studies Using Both Allosteric and Orthosteric Radioligands Reveal Probe Dependence. The functional GTPgS-binding experiments above establish that LY2119620 positively modulates the G proteincoupled response of the M 2 /M 4 receptor subtypes in a probedependent manner. To further elucidate this probe dependence, we set up a series of saturation-binding experiments to view these effects from both the allosteric and orthosteric ligand-binding perspective. The (Fig. 4A) ; the K d values ranged from 11.2 6 1.17 nM for iperoxo to 16.9 6 0.700 nM for Oxo-M. Similarly, at the M 4 receptor, the B max for Oxo-M was 1110 6 157 fmol/mg, which was significantly greater than ACh (456 6 55.0 fmol/mg) or iperoxo (291 6 19.9 fmol/mg) (Fig. 4B) ; the K d values ranged from 2.35 6 0.237 nM for ACh to 2.93 6 0.205 nM for iperoxo. Control experiments at varying concentrations of orthosteric agonist (0, 10, 100, 1000 mM) were performed and showed that no further cooperativity (increase in the B max ) was observed between 10 and 100 mM. This indicated that a lack of orthosteric binding site saturation was not the primary cause for the observed B max differences. These results led us to hypothesize that the [ 3 H]LY2119620 binding was only reporting the receptor G protein-coupled state (RG) population; thus, changes in the receptor G protein coupling, in this study arising from differences in the efficiency of the orthosteric ligand to couple G protein, manifest as an apparent change in B max . To test whether similar receptor G proteincoupled effects could also be observed from the orthosteric site, experiments were repeated with the orthosteric radioligand, Figure 4 , C and D, shows a B max increase at the M 2 receptor from 793 6 1.95 fmol/mg to 2850 6 162 fmol/mg upon addition of 10 mM LY2119620 (Fig.  4C ), and about a 5-fold increase in B max at the M 4 receptor, 284 6 18.3 fmol/mg to 1340 6 42.2 fmol/mg (Fig. 4D) . The response was fully saturated at 10 mM LY2119620. The K d values for the M 2 receptor are approximately 2 nM, and for the M 4 receptor decreases slightly from 3.27 6 0.722 to 1.17 6 0.185 nM upon LY2119620 addition (Table 2) Figure 4 , E and F, shows that [ 3 H]Oxo-M-binding curve has an increase in B max from 721 6 114 nM to 1890 6 271 nM when 1 mM LY2119620 was added and that this increase was significantly reversed, B max of 995 6 164 nM, by addition of The change in the EC 50 value of agonists ACh, Oxo-M, and iperoxo upon addition of the allosteric ligand, LY2119620, was measured using a G protein-coupled functional assay. Values presented represent the means 6 S.E.M. of three independent experiments conducted in duplicate.
EC 50 Agonist Alone LY2119620 (10 mM) GppNHp at the M 2 receptor (Fig. 4E) . Similar trends were observed at the M 4 receptor; however, the reversal was not seen to be as complete under the conditions tested (Fig. 4F) . Overall, these saturation studies support the hyopothesis that LY2119620 probe dependence reflects an allosteric enhancement of the proportion of RG or G protein-coupled activestate receptors. Figure 5 shows that, upon addition of the allosteric ligand, the dissociation rate of [ 3 H]NMS was retarded (Fig. 5) , although no overall changes, in the affinity of NMS for either the M 2 or M 4 receptors upon binding of the allosteric ligand LY2119620, were observed (Supplemental Fig. 2 ). The magnitude of this dissociation rate affect varied with receptor subtype. The dissociation rate of [ 3 H]NMS from the M 2 receptor in the presence of iperoxo was 0.347 6 0.0203 minute 21 and, upon addition of LY2119620, slowed to 0.016 6 0.00790 minute 21 (Fig. 5A) ; this relative change was very similar at the M 4 receptor (k off reduced from Fig. 5B ). At the M 4 receptor the trends remained consistent with that observed at the M 2 receptor, although the potency of LY2119620 was greater (Fig. 5, A and B) ; Table 3 summarizes all t 1/2 and k off rates for both the M 2 and M 4 receptors. Overall, these results are consistent with a model in which LY2119620 is highly cooperative with orthosteric agonist binding, being more positively cooperative at the M 4 relative to M 2 receptor.
Additional [ 3 H]NMS displacement studies were performed to provide evidence that allosteric binding by LY2119620 could be observed to alter the binding affinity of the orthosteric ligand, reflected as a change in K i of the agonist. Figure 5 , C and D, shows the competitive IC 50 value for iperoxo in the absence or presence of LY2119620 and shows that the IC 50 values for agonist competition of [ ]NMS data thus demonstrate that cooperativity between LY2119620 and orthosteric ligand sites can also be observed at the receptor-binding level (LY2119620 acts as a PAM).
Discussion
This study provides insight into the molecular pharmacology of the small molecule, LY2119620, which proves to be a M 2 /M 4 receptor-selective PAM. Three major impacts of this work are as follows: the identification of a novel M 2 /M 4 receptor allosteric pharmacological tool that can be used to inform the development of treatments for neurologic disorders such as schizophrenia; the exploration of probe dependence and the molecular mechanisms by which allosteric molecules may act upon a GPCR and its signaling properties; and the characterization of the potent muscarinic-agonist iperoxo at the muscarinic M 2 and M 4 receptor and its modulation by an allosteric ligand.
The GTPgS-binding assays performed with LY2119620 demonstrate that LY2119620 displays modest allosteric agonism (Fig. 2C) and positively modulates the functional G protein-signaling ability of an agonist at the M 2 /M 4 receptor subtypes (Fig. 3) . The degree of cooperativity between the orthosteric-allosteric ligands was found to vary depending on the agonist pairings, indicating probe dependence. Probe dependence for allosteric ligands has been reported before (Gregory et al., 2010; Leach et al., 2010; Luttrell and Kenakin, 2011; Suratman et al., 2011; Valant et al., 2012 ; see also the recent review by Wootten et al., 2013) and proves a significant challenge when trying to validate the suitability of a drug candidate. As the pharmacology can be dramatically impacted by this probe dependence, LY2119620 was evaluated with its natural agonist ACh, as well as full agonists Oxo-M and iperoxo. The results of the functional studies showed that LY2119620 enhanced the potency of all three agonists at the M 2 receptor: ACh 5-fold (34.3 6 8.62 nM to 7.38 6 2.03 nM); Oxo-M 10-fold (22.2 6 3.51 nM to 2.04 6 0.561 nM); and iperoxo 11-fold to a subnanomolar EC 50 of 71.1 6 11.5 pM. At the M 4 receptor, the increase in potency was 22-fold for ACh (219 6 42.8 nM to 10.0 6 2.06 nM) and 47-fold for Oxo-M (123 6 19.4 nM to 2.65 6 1.05 nM); again the potency of iperoxo dropped to subnanomolar (EC 50 5 0.104 nM). Further exploration of whether these orthosteric-allosteric pairing effects seen in G protein signaling also manifest in other downstream signaling pathways such as extracellular regulated kinase 1/2 phosphorylation, glycogen synthase kinase 3b phosphorylation, and receptor internalization is being pursued in subsequent studies.
The radioligand saturation-binding studies presented in Fig. 4 were performed to explore whether probe dependence was also observed at the receptor-ligand-binding level. The tritiated ligand, [ 3 H]LY2119620, allowed the binding of ACh, Oxo-M, and iperoxo under identical experimental conditions.
The results of these [
3 H]LY2119620 studies showed that the number of allosteric receptor sites differed in an agonistdependent manner and that this change in B max was not accompanied by a readily measurable change in K d (Fig. 4, A and B). The lack of two-site binding curves indicated that LY2119620 was not binding to low-and high-affinity receptor site populations. Hypothesizing that LY2119620 binding was only able to monitor the coupled active-state receptors (RG), the differences in B max perhaps arose because the various orthosteric ligands had differential abilities to promote the receptors into the RG state. Switching the radioligand to the orthosteric site, saturation-binding studies were conducted with [
3 H]Oxo-M in the presence of various concentrations of LY2119620 (Fig. 4, C-F) . The [ 3 H]Oxo-M results suggest that LY2119620 binding to the allosteric site could also increase the number of orthosteric binding sites available (Fig. 4, C  and D) . Furthermore, Fig. 4 , E and F, showed that these allosteric-induced Oxo-M sites could be blocked by decoupling the G protein from the receptor (incubating the receptors with GppNHp) and shifting the receptor to a low-activity state. To summarize, the [ 3 H]Oxo-M saturation studies suggested that the allosteric ligand LY2119620 binds preferential to coupled active-state receptors and can promote the number of receptors in this RG state. A similar redistribution of high-and lowaffinity receptor sites was observed in a LY2033298, a congener M 4 receptor PAM, study . Overall, the allosteric and orthosteric radioligand studies suggest that both Oxo-M and LY2119620 can place the M 2 and M 4 receptors into an active G protein-bound state. Deeper insight into the complex interplay between the orthosteric, allosteric, and G protein-coupled sites is now possible with the availability of tool compounds such as [ 3 H]LY2119620. Additional radioligand studies were also performed to demonstrate that LY2119620 modulated the binding of agonists at the orthosteric site. Specifically, competitive binding experiments utilizing the [ 3 H]NMS radioligand demonstrated that LY2119620 binding at the allosteric site slowed the dissociation of NMS in the presence of the agonist iperoxo (Fig. 5, A and B) . In addition, equilibrium [ 3 H]NMS saturation experiments showed that LY2119620 binding altered the affinity of iperoxo for the orthosteric site; the K i for iperoxo decreased from 25.1 6 14.5 nM to 0.878 6 0.343 nM at the M 2 receptor (Fig. 5, C and D) . To summarize, these studies present experimental evidence that LY2119620 acts as a potent PAM for the M 4 . M 2 receptor Iperoxo 10.6 6 0.257 0.065 6 0.00160 73.9 6 0.945 0.00938 6 0.00012 30.6 6 5.12 0.0242 6 0.00450 20.0 6 3.12 0.0365 6 0.00587 subtypes, as measured by both receptor binding (Fig. 5) and G protein functional activity (Fig. 3) . Another important result of this study was the characterization of the potent agonist, iperoxo, to date described in the literature as a M 2 superagonist (Kloeckner et al., 2010; Bock et al., 2012; Schrage et al., 2013) , and its modulation by an allosteric ligand. Originating from screens for novel derivatives of Oxo-M (Dallanoce et al., 1999) , iperoxo was found to possess both superior affinity and efficacy over ACh. Our work recapitulated previous findings that iperoxo possessed an EC 50 of 2.12 6 0.0953 nM at the M 2 receptor (EC 50(Ach) /EC 50(Iperoxo) 5 56-fold; Fig. 2A) , and then expanded the pharmacological characterization to the M 4 receptor subtype and found similar nanomolar potency (EC 50 5 8.47 6 3.00 nM, and 61-fold enhancement in the EC 50(Ach) /EC 50(Iperoxo) ; Fig. 2B ). Additionally, the saturation-binding and functional GTPgS studies showed that this high efficacy agonist was able to be further modulated by binding of an allosteric compound ( Fig. 3; Fig. 5 ).
This study of LY2119620 has explored the molecular mechanism of this M 2 /M 4 receptor subtype-selective PAM mainly in a recombinant cellular system. Moreover, these studies corroborate and extend the initial characterization of the functional cooperativity observed between LY2119620 and iperoxo in (Kruse et al., 2013) . The availability of a radiolabeled form of LY2119620, NMS, and Oxo-M ligands enabled the discovery that LY2119620 binding to the allosteric site increases the proportion of receptors in the G protein-coupled active state. This insight may have implications in light of the emerging structural studies, such as the recent active-state M 2 receptor crystal structure with iperoxo and LY2119620 docked in their respective binding sites (Kruse et al., 2013) . Although the crystal structure suggests that it is the entry of the orthosteric ligand that is critical for receptor movements leading to the appropriate unfolding of the intracellular domain region for G protein coupling, it is clear that the allosteric vestibule can also contribute to this switch to a permissive G protein-binding state. Ultimately, our work in the development of the M 2 /M 4 receptor-selective PAM, LY2119620, supports these crystallization efforts, which provide the first atomic level understanding of such activation and allosteric modulation mechanisms of the muscarinic receptor family.
